AI Business LensTHE BUSINESS OF AI, FOR PEOPLE WHO TEACH IT OR LEARN FROM IT
TechCrunch · September 24, 2026 · On the brief until October 8, 2026

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

MedicinePharmacyEntrepreneurship
THE AI ANGLE
Discovering new drug candidates from nature

Enveda raised $311 million to fund clinical trials for drugs derived from plants and microbes. The startup uses artificial intelligence to find these natural compounds and speed up drug discovery. This funding round doubles the company valuation to $2 billion.

Summary written by AI Business Lens with an AI model from the article at techcrunch.com. It is not the article, and the publisher has not reviewed it. For publishers.

THE TEACHING ANGLE
We should discuss whether artificial intelligence can reliably accelerate the journey of natural compounds from raw discovery to approved clinical treatments.

Read the original at techcrunch.com   Generate teaching or study materials

Instructors get discussion guides, assignments, and mini-cases. Students and readers get a plain summary, points to raise, an exercise, and a self-check. All built from the full article. A free account saves stories and gives you three generations. Stories stay on the brief for 14 days. After that this page keeps the link to the original.

More in Medicine